I can imagine it must be confusing when more than one person on here has a good grasp of the subject matter.
for those investors interested in other things happening in this disease landscape , worth spending a few mins checking out what Novocure is doing with TT fields device. They’re already approved for glioblastoma in US. Advanced development programme now in locally adv. pc and quite some striking similarity to OSL’s programme . They also completed a small single arm feasibility trial published in Pancreatology (Rivera et al) in Jan 2019, combining TTF with gem or gem + abr though allowed stages 3&4 pc. Strong PFS results >10 months with device plus best chemo. . They’re now onto phase 3 pivotal which looks identical in design to what OSL has previously informed market they’d be doing. Novocure’s is a 556 patient RCT in L.A. pancreatic cancer , TTF plus gemcitabine-abraxane vs gem- abraxane alone as control. (Panova-3 trial).
- Forums
- ASX - By Stock
- OSL
- Ann: Oncosil breakthrough device receives CE Marking approval
Ann: Oncosil breakthrough device receives CE Marking approval, page-150
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Breakthrough programs slash healthcare events, driving a significant A$1.8M+ annual revenue boost
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
Add OSL (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.001(7.69%) |
Mkt cap ! $52.97M |
Open | High | Low | Value | Volume |
1.4¢ | 1.4¢ | 1.3¢ | $56.50K | 4.041M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 12011630 | 1.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.4¢ | 6141425 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
15 | 9458984 | 0.013 |
18 | 9551684 | 0.012 |
18 | 8704466 | 0.011 |
17 | 11298020 | 0.010 |
11 | 4321222 | 0.009 |
Price($) | Vol. | No. |
---|---|---|
0.014 | 4941425 | 7 |
0.015 | 2383570 | 9 |
0.016 | 4392825 | 5 |
0.017 | 5155548 | 3 |
0.018 | 1632208 | 4 |
Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
Featured News
CC9
Chariot Corporation (ASX:CC9) refines Black Mountain strategy, launching Pilot Mine to seize U.S. lithium opportunity
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
OSL (ASX) Chart |